T50 - the new treatment target for patients with chronic kidney disease


We are working to improve health and disease management of patients worldwide


CALCISCON's patented T50 test is an improved proxy for phosphate toxicity. Our scalable test kit and data analysis software are already approved in Europe (CE).

Our breakthrough innovation provides a new unifying treatment target for chronic kidney disease patients and has large market potential. 

We are currently raising a series A round. 

Please contact for further information:

Andreas Pasch, andreas.pasch@calciscon.com or

Vincent Linder, vincent.linder@calciscon.com



Calciscon is supported by: